Amgen (AMGN) Stock & Financials
Data as of (550 days ago)|Source: SEC EDGAR
Amgen (AMGN) is a biotechnology company. The company reports annual revenue of $36.0B and net income of $7.0B. Its profit margin is 19.5%.
What to check next
For informational purposes only. Not investment advice. Data may be delayed or inaccurate; verify independently. The information on this page is for informational purposes only and does not constitute investment advice, financial advice, or any recommendation. Billiver does not recommend buying, selling, or holding any security. Past performance is not indicative of future results. Data may be delayed and accuracy is not guaranteed. All investment decisions are solely your responsibility. Verify information independently and consult a qualified financial advisor before investing.
Amgen Key Financials(TTM Est.)
Data from SEC EDGAR filings. TTM = Trailing Twelve Months.
Amgen Financial Health ScoreFY2025
Moderate health; several metrics need attention
+2 pts YoYThis Financial Health Score is a proprietary metric calculated from SEC EDGAR filings for educational and informational purposes only. It does not constitute investment advice or a recommendation to buy or sell any security. Results vary significantly by industry. Conduct your own research before making investment decisions.
Data Highlights
- Altman Z-Score 0.55 (distress zone, below 1.8 threshold)
- Strong return on equity: 72.8%
Data sourced from SEC EDGAR filings. Not investment advice.
Amgen Recent Events
Source: SEC EDGAR 8-K Filings
5-Year Revenue & Net Income Trend
Chart shows fiscal year data from SEC EDGAR filings. Hover over data points for details.
As of FY2025 · SEC Form 10-K · Last checked Jun 30, 2026
Revenue Breakdown (FY2024)
See Amgen detailed breakdown →As of FY2024 · SEC 10-K Annual Filings · Updated Jan 28, 2026
About Amgen
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics.
- Industry
- Biotechnology
Valuation
Valuation Data UnavailablePrice-based valuation metrics (P/E, P/B) require real-time stock price data which is not included in SEC filings.
Benjamin Graham: Graham recommended P/E ratio not exceed 15 for reasonable valuation. Understanding valuation metrics
Profitability
Positive Marginsvs 14.8% sector median / 21.8% avg
Generates $72.8 in profit for every $100 of shareholder equity. Higher than 87% in Health Care.
vs 18.1% sector median / 15.0% avg
Keeps 19 cents of every dollar in revenue as profit. Higher than 54% in Health Care.
4th consecutive year of revenue growth.
* Some quarterly data is missing. Values are calculated based on annual report figures.
Profit margin of 19.5% is above 10%.
Warren Buffett: Buffett looks for consistent ROE above 20% as a sign of competitive advantage. How to evaluate profitability
Financial Health
High Leveragevs 1.48 sector median / 2.01 avg
Carries $5.67 in debt for every $1 of equity. Lower debt than 17% in Health Care. Debt has increased over the past 5 years.
Debt-to-equity ratio of 5.67 is above 1.5.
Peter Lynch: Lynch: normal balance sheet has 75% equity, 25% debt. Understanding financial health
Dividend
Dividend Data UnavailableDividend yield data is not available from SEC filings. Check the company's investor relations page for dividend information.
As of FY2025 · SEC Form 10-K · Last checked Jun 30, 2026
Amgen 10-Year Revenue, Profit & Cash Flow History
Annual Financials
FY2025 - FY2016| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $36.8B(+10.0%) | $33.4B(+18.6%) | $28.2B(+10.9%) | $25.4B(+8.8%) | $23.4B(-1.6%) | $23.7B(+3.9%) | $22.8B(-0.6%) | $23.0B(+6.1%) | $21.7B(+8.0%) | $20.1B(-7.4%) |
| Net Income | $7.7B(+88.5%) | $4.1B(-39.1%) | $6.7B(-7.5%) | $7.3B(-7.4%) | $7.8B(-6.6%) | $8.4B(+324.2%) | $2.0B(-74.4%) | $7.7B(+11.3%) | $6.9B(+34.5%) | $5.2B(-25.7%) |
| Total Assets | $90.6B | $91.8B | $97.2B | $65.1B | $61.2B | $62.9B | $59.7B | $66.4B | $80.0B | $77.6B |
| Total Debt | $54.6B | $60.1B | $64.6B | $38.9B | $33.3B | $33.0B | $29.9B | $33.9B | $35.3B | $34.6B |
| Total Equity | $8.7B | $5.9B | $6.2B | $9.4B | $9.7B | $12.5B | $25.2B | $29.9B | $28.1B | $25.8B |
| Profit Margin | 21.0% | 12.2% | 23.8% | 28.6% | 33.6% | 35.4% | 8.7% | 33.6% | 32.0% | 25.7% |
| ROE | 89.1% | 69.6% | 107.8% | 77.2% | 81.1% | 67.2% | 7.8% | 25.9% | 24.7% | 20.0% |
| ROA | 8.5% | 4.5% | 6.9% | 11.2% | 12.8% | 13.3% | 3.3% | 11.6% | 8.7% | 6.6% |
Quarterly Financials
Last 8 quarters| Metric | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $8.1B | $24.3B | $15.8B | $7.4B | $20.0B | $13.1B | $6.1B | $19.5B |
| Net Income | $1.7B | $3.5B | $633.0M | $-113,000,000 | $2.8B | $2.8B | $2.8B | $1.5B |
| Total Assets | $90.6B | $91.8B | $91.8B | $91.8B | $97.2B | $97.2B | $97.2B | $65.1B |
As of FY2025 · SEC Form 10-K · Last checked Jun 30, 2026
Insider Trading
Source: SEC EDGAR Form 4 filings. Only purchase (P) and sale (S) transactions shown.
Amgen Dividend Safety Analysis & Growth History
Dividend Status
Dividend PayerThis company pays dividends. Historical dividend data shown below.
5-year dividend CAGR: -6.2%.
Annual Dividends
2016 - 2025| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend/Share | $4.15 | $1.32 | $5.41 | $5.95 | $6.56 | $5.46 | $7.95 | $8.64 | $9.13 | $4.76 |
| YoY Growth | - | -68.2% | +309.9% | +10.0% | +10.3% | -16.8% | +45.6% | +8.7% | +5.7% | -47.9% |
| Payments | 1 | 1 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 2 |
| Increased | - | No | Yes | Yes | Yes | No | Yes | Yes | Yes | No |
Learn more:Dividend investing guideHow to evaluate dividend safety
As of FY2025 · SEC XBRL dividend facts · Last checked Jul 1, 2026
Amgen Free Cash Flow & Dividend Coverage
Generates approximately $22M in free cash flow per day.
Cash Flow History
FY2016 - FY2025| Metric | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating CF | $9.0B | $9.7B | $10.4B | $11.2B | $11.3B | $9.2B | $10.5B | $8.5B | $11.5B | $10.0B |
| CapEx | -$718.0M | -$594.0M | -$738.0M | -$664.0M | -$738.0M | -$618.0M | -$608.0M | -$1.1B | -$1.1B | -$1.9B |
| Free Cash Flow | $8.2B | $9.1B | $9.6B | $10.5B | $10.6B | $8.5B | $9.9B | $7.4B | $10.4B | $8.1B |
| FCF Margin | 41.0% | 42.2% | 41.8% | 46.0% | 44.5% | 36.5% | 38.9% | 26.1% | 31.1% | 22.0% |
Source: SEC EDGAR 10-K filings. FCF = Operating Cash Flow - Capital Expenditures. Free cash flow guide
As of FY2025 · SEC Form 10-K · Last checked Jun 30, 2026
Amgen Risk Factors
Company-disclosed SEC risk factors
Risk factors are disclosed by the company in its SEC Form 10-K, Item 1A. Billiver does not classify or summarize company-specific legal, operational, financial, or market risks here.
Sector context: Health Care. This is not a Billiver risk assessment for AMGN.
Source note: the SEC Form 10-K includes Item 1A, "Risk Factors." The full risk-factor text should be read from the company’s own SEC filing.
Amgen FAQ
What is Amgen's annual revenue?
Amgen (AMGN) reported $36.0 billion in trailing twelve-month (TTM) revenue. This financial data is compiled from SEC EDGAR 10-K filings.
Is Amgen profitable?
Yes, Amgen is profitable with a 19.5% net profit margin and $7.0 billion in net income (TTM). All figures from SEC EDGAR 10-K filings.
Does Amgen pay dividends?
Yes, Amgen pays regular dividends. View the full dividend history and payout analysis on this page.
What is Amgen's financial health score?
Amgen has a financial health score of 61/100 (Grade: C), evaluating profitability, solvency, liquidity, and growth based on SEC EDGAR data.
How many years of Amgen financial data are available?
10 years of financial data are available for Amgen from FY2016 to FY2025. All figures are compiled from SEC EDGAR 10-K filings.